SCHEMBL5887652

SCHEMBL5887652

Cc1nc(N2CCN(C(=O)OCc3ccccc3)CC2)nc2c1ccc(=O)n2-c1ccc(C(=O)NCc2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CYP2C19 P33261 1/20 0.42
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CTNNB1 P35222 2/20 0.40
TCF7L2 Q9NQB0 2/20 0.40
MAPK14 Q16539 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
EPHX2 P34913 2/20 0.39
CETP P11597 1/20 0.38
MAOA P21397 1/20 0.38
NAMPT P43490 1/20 0.38
MAPK8 P45983 2/20 0.38
ENPP2 Q13822 1/20 0.38
HDAC1 Q13547 1/20 0.37
BRAF P15056 2/20 0.37
PPARG P37231 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887351 0.94 SMN1; SMN2 (0.43) SMN1; SMN2MEN1KMT2ACYP2C19HTT
SCHEMBL5887410 0.93 SMN1; SMN2 (0.46) SMN1; SMN2MEN1KMT2ACYP2C19HTT
SCHEMBL5887578 0.92 SMN1; SMN2 (0.42) SMN1; SMN2MEN1KMT2ACYP2C19HTT
SCHEMBL5887458 0.90 MEN1 (0.46) SMN1; SMN2MEN1KMT2ACYP2C19HTT
SCHEMBL5887532 0.90 CA1 (0.42) SMN1; SMN2MEN1KMT2ACYP2C19HTT
SCHEMBL5886912 0.89 ME2 (0.43) SMN1; SMN2MEN1KMT2ACYP2C19NPSR1
SCHEMBL5886889 0.89 MAPK10 (0.45) SMN1; SMN2MEN1KMT2ACYP2C19MAPK14
SCHEMBL5886918 0.89 CTNNB1 (0.43) SMN1; SMN2MEN1KMT2ACYP2C19CTNNB1
SCHEMBL5886763 0.89 SMN1; SMN2 (0.42) SMN1; SMN2MEN1KMT2ACYP2C19HTT
SCHEMBL5886869 0.88 HIF1A (0.47) MEN1KMT2AEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP SMN1; SMN2 2219/4885MEN1 2183/4885KMT2A 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.